Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 638, Issue 1-2, 2008, Pages 66-74

  Buchmann, Albrecht ^a   Karcier, Züleyha ^a   Schmid, Benjamin ^a   Strathmann, Julia ^a   Schwarz, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

B raf; Gene mutation; Ha ras; Mouse hepatocarcinogenesis; Strain specific selection

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; B RAF KINASE; DIETHYLNITROSAMINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENETIC DIFFERENCE; GENETIC SUSCEPTIBILITY; LIVER CARCINOGENESIS; NONHUMAN; ONCOGENE H RAS; PREVALENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BASE SEQUENCE; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SPECIES SPECIFICITY;

ANIMALIA; MUS;

EID: 37849003214     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.08.015     Document Type: Article

References (40)

1. Balmain A., and Harris C.C. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21 (2000) 371-377
2. Rangarajan A., and Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3 (2003) 952-959
3. Maronpot R.R., Fox T., Malarkey D.E., and Goldsworthy T.L. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101 (1995) 125-156
4. Buchmann A., Bauer-Hofmann R., Mahr J., Drinkwater N.R., Luz A., and Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc. Natl. Acad. Sci. USA 88 (1991) 911-915
5. Dragani T.A., Manenti G., Colombo B.M., Falvella F.S., Gariboldi M., Pierotti M.A., and Della Porta G. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene 6 (1991) 333-338
6. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
7. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3 (2003) 459-465
8. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7 (2007) 295-308
9. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653 (2003) 25-40
10. Wellbrock C., Karasarides M., and Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5 (2004) 875-885
11. Schreck R., and Rapp U.R. Raf kinases: oncogenesis and drug discovery. Int. J. Cancer 119 (2006) 2261-2271
12. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard Jones K., Maitland N., Chenevix Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
13. Ikenoue T., Hikiba Y., Kanai F., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., Kawakami T., Aragaki J., Matsumura M., Kawabe T., and Omata M. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63 (2003) 8132-8137
14. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
15. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
16. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., and Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62 (2002) 6451-6455
17. Singer G., Oldt III R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., and Shih I.-M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 (2003) 484-486
18. Jaworski M., Buchmann A., Bauer P., Riess O., and Schwarz M. B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 24 (2005) 1290-1295
19. Drinkwater N.R., and Ginsler J.J. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 7 (1986) 1701-1707
20. Gariboldi M., Manenti G., Canzian F., Falvella F.S., Pierotti M.A., Della Porta G., Binelli G., and Dragani T.A. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res 53 (1993) 209-211
21. Dragani T.A., Manenti G., Gariboldi M., De Gregorio L., and Pierotti M.A. Genetics of liver tumor susceptibility in mice. Toxicol Lett. 82-83 (1995) 613-619
22. Balmain A., and Nagase H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet. 14 (1998) 139-144
23. Bilger A., Bennett L.M., Carabeo R.A., Chiaverotti T.A., Dvorak C., Liss K.M., Schadewald S.A., Pitot H.C., and Drinkwater N.R. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 167 (2004) 859-866
24. Kalkuhl A., Troppmair J., Buchmann A., Stinchcombe S., Buenemann C.L., Rapp U.R., Kaestner K., and Schwarz M. p21Ras downstream effectors are increased in activity or expression in mouse liver tumors but do not differ between ras-mutated and ras-wild-type lesions. Hepatology 27 (1998) 1081-1088
25. Buchmann A., Mahr J., Bauer-Hofmann R., and Schwarz M. Mutations at codon 61 of the Ha-ras proto-oncogene in precancerous liver lesions of the B6C3F1 mouse. Mol. Carcinogen 2 (1989) 121-125
26. Strathmann J., Schwarz M., Tharappel J.C., Glauert H.P., Spear B.T., Robertson L.W., Appel K.E., and Buchmann A. PCB 153, a non-dioxin-like tumor promoter, selects for beta-catenin (Catnb)-mutated mouse liver tumors. Toxicol. Sci. 93 (2006) 34-40
27. Balmain A., and Brown K. Oncogene activation in chemical carcinogenesis. Adv. Cancer Res. 51 (1988) 147-182
28. Loktionov A., Hollstein M., Martel N., Galendo D., Cabral J.R., Tomatis L., and Yamasaki H. Tissue-specific activating mutations of Ha- and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA. Mol. Carcinog. 3 (1990) 134-140
29. Manam S., Storer R.D., Prahalada S., Leander K.R., Kraynak A.R., Ledwith B.J., van Zwieten M.J., Bradley M.O., and Nichols W.W. Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice. Cancer Res. 52 (1992) 3347-3352
30. Mercer K., Giblett S., Green S., Lloyd D., DaRocha Dias S., Plumb M., Marais R., and Pritchard C. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65 (2005) 11493-11500
31. Storm S.M., and Rapp U.R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol. Lett. 67 (1993) 201-210
32. Chong H., Vikis H.G., and Guan K.L. Mechanisms of regulating the Raf kinase family. Cell Signal 15 (2003) 463-469
33. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
34. Repasky G.A., Chenette E.J., and Der C.J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 14 (2004) 639-647
35. Jaworski M., Ittrich C., Hailfinger S., Bonin M., Buchmann A., Schwarz M., and Köhle C. Global gene expression in Ha-ras and B-raf mutated mouse liver tumors. Int. J. Cancer 121 (2007) 1382-1385
36. Aydinlik H., Nguyen T.D., Moennikes O., Buchmann A., and Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 20 (2001) 7812-7816
37. Calvisi D.F., Ladu S., Factor V.M., and Thorgeirsson S.S. Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 25 (2004) 901-908
38. Schwarz M., Buchmann A., Stinchcombe S., Luebeck G., Moolgavkar S., and Bock K.W. Role of receptors in human and rodent hepatocarcinogenesis. Mutat. Res. 333 (1995) 69-79
39. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., Hauss J., and Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
40. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6 (2005) 827-837